Last March, Ziopharm Oncology executives said they walked out of an FDA meeting with “positive guidance” on the design of a Phase 3 clinical trial for its experimental IL-12 gene therapy in patients with glioblastoma, the type of aggressive brain cancer afflicting U.S. Sen. John McCain.
Four months later, Ziopharm still hasn’t offered investors any specific details about that “successful” FDA meeting, or a similar meeting held with European regulators.
About the Author Reprints
